Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
about
Data Access and Sharing: Are we being transparent about clinical research? Let's do what's right for patients.Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsA novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.Surrogate markers of overall survival in metastatic colorectal cancer: an evolving challenge still more complex with repeat surgery.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Bevacizumab: a review of its use in advanced cancer.First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma.Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer.Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A retrospective analysis of 830 patients stratified by the 8th edition of
P2860
Q30491337-DC16A8A3-79B8-4330-8A06-8FB2EAC060BAQ34716556-4E1E591B-28E8-450A-830F-C7A685442C5BQ35855330-15B3934F-AFA3-47B5-83A8-8491C769F127Q36173497-3110DBAE-0212-4A5B-AC95-B5735B4E3108Q37402280-8BEDDC67-CEC1-4844-B9F7-244CC3911581Q38233353-F9A64380-144D-49D6-B517-5857E01235A2Q38260176-48E9AE21-D97E-4B3D-8279-031106415730Q38550942-B4D2E091-A97A-4B80-810A-19A9D49516F4Q38880510-F759FFA4-B098-45F2-B664-AF86B6096D81Q40754987-D210B940-91CD-4BE8-AC16-1E3BDCCED502Q46202175-FEA47313-03EA-4A8B-A546-87C9728B46B0Q47591645-1B99AD8F-1CA7-4422-8064-F1C0E64F617BQ48014067-E1B4F281-287F-4B50-8BBB-65151E0C34DDQ52650529-5D04FD03-7F81-4D9F-B9A9-876980166D07Q53717818-DAF39CE5-6E1F-48C7-95D5-91EEC0745C32Q55026900-67FE6137-CB7E-4CFC-B0A4-D9935D7213F5Q55119011-769981DF-E4F1-44AE-A92E-8CB0F4936C15Q57116407-98545AF8-892F-4358-8E8D-33E11EEC8C8B
P2860
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progression-free survival as a ...... tastatic renal cell carcinoma.
@en
Progression-free survival as a ...... tastatic renal cell carcinoma.
@nl
type
label
Progression-free survival as a ...... tastatic renal cell carcinoma.
@en
Progression-free survival as a ...... tastatic renal cell carcinoma.
@nl
prefLabel
Progression-free survival as a ...... tastatic renal cell carcinoma.
@en
Progression-free survival as a ...... tastatic renal cell carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Progression-free survival as a ...... tastatic renal cell carcinoma.
@en
P2093
Brian Rini
Eric J Small
Susan Halabi
Walter M Stadler
P2860
P356
10.1002/CNCR.28221
P407
P577
2013-10-08T00:00:00Z